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1. Introduction 
 
One of the most important consequences of the reduction in coronary blood flow due 
to acute myocardial ischemia is the occurrence of severe ventricular tachyarrhythmias, which 
remain one of the major causes of sudden cardiac death (SCD) in modern societies. Although 
the underlying mechanisms of these acute arrhythmias are many and varied, it is certain that 
the ischemia-induced rapid ionic alterations and the subsequent inhomogeneous conduction 
may play an essential role.  
The problem of sudden cardiac death from ventricular fibrillation during coronary 
artery occlusion or reperfusion, outside the hospital setting is still one of the biggest 
challenges facing clinical cardiology. Despite all attempts, e.g. the introduction of mobile 
coronary care units and implantable defibrillators, as well as the training of non-medical 
personnel in the use of these appliances, more than half of the cardiovascular deaths can be 
attributed to sudden ventricular fibrillation. Since drug therapy has proved to be largely 
ineffective except in the clinical setting, understanding the underlying mechanisms that lead 
to these life-threatening ventricular arrhythmias is crucial for developing novel therapeutic 
strategies. 
In the past few decades many attempts have been made on protecting the myocardium and 
thus preventing the heart from the severe consequences of ischemia/reperfusion injury. One of 
these attempts was made by Murry and colleagues 1 in 1986 where they observed that the heart 
responds to brief ischemia/reperfusion insults with an increased tolerance, rather than with 
cumulating ischemic damage, during a subsequent, more prolonged episode of ischemia. This 
phenomenon was termed as „ischemic preconditioning”. The fact, that the heart can be 
protected against severe, often fatal injuries by similar, but sub-lethal ischemic stress has 
raised considerable interest both in experimental and also in clinical cardiovascular research. 
The short periods of ischemia are now commonly applied to protect the heart from ischemic 
injury during human coronary by-bass surgery 2. There is also evidence that not only the short 
ischemic episodes but other stimuli, such as rapid cardiac pacing 3 and vigorous physical 
exercise 2 can also provide protection. Numerous epidemiologic studies have revealed that 
regular exercise reduces morbidity and mortality in patients with coronary artery diseases 
 - 9 - 
(CAD) 2,  4. Moreover, it has been shown that exercise attenuates the risk factors for CAD, such 
as hypertension, hyperlipidemia, diabetes, obesity. However, the exact mechanisms by which 
the exercise-induced protection attains are still not fully elucidated. The main purpose of the 
studies, described in the present thesis, was to explore the mechanisms involved in the early 
and the delayed antiarrhythmic effects of preconditioning induced by brief coronary artery 
occlusions and by physical exercise, with particular attention of the role of nitric oxide and 
reactive oxygen species (ROS). 
1.1. Consequences of acute myocardial ischemic injury 
After occlusion of a coronary artery the blood supply dramatically decreases in the 
affected tissue, however, the oxygen and energy demand of the working myocardium has not 
changed. Myocardial energy is formed of ATP, which is produced by the oxidative 
metabolism of the carbohydrates and fatty acids. There are just two energy stores exist in the 
myocardium: the glycogen and the high energy phosphates 6- 7. Besides the low oxygen level 
the metabolic pathways change from aerobic to anaerobic process to produce ATP 6. However 
these pathways evoke the drastic decrease of intracellular and extracellular pH, due to the 
accumulation of lactic acid 8. 
During occlusion the ischemia induces the development of ischemic metabolites, such 
as lactate, platelet activation factor 9, cytokines 10, reactive oxygen species (ROS) 11, NO· and 
other reactive nitrogen species (NOS) 12 as well as arachidonic acid 13. These metabolites 
contribute to the myocardial ischemic injury development, the ionic alteration and 
dysfunction in contractility. These factors altogether drive the myocardium to 
arrhythmogenesis. 
Electrocardiographically the ischemic event is characterized by marked TQ-interval 
shortening 14 and ST-segment elevation 15. This alteration comes from the early changes in 
transmembrane action potential (AP) and the delayed changes in electrical cell-to-cell 
coupling 15. The ionic alteration during myocardial ischemia modifies the AP: i.e. shortens its 
duration and delays the refractoriness, whereas decreases the amplitude of AP 16. Moreover the 
ischemic conditions reduce the resting membrane potential and draw it closer to the threshold 
potential 17. 
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1.2. The acute ischemia and reperfusion-induced ventricular 
arrhythmias  
The important consequences of acute ischemic injury are the occurrence of the life-
threatening ventricular arrhythmias. The reduced resting membrane potential, slowed 
conduction, the ionic and metabolic alterations that are present under ischemic conditions, 
lead to the generation of severe arrhythmias, by provoking spontaneous after-
depolarization 16, 18. On the other hand, the unidirectional conduction block and the delay in 
impulse conduction in the ischemic myocardium favour the occurrence of the re-entry type 
arrhythmias 17. The impulse spreading in some part of the tissue is prevented by the 
conduction blocks. It blocks the retrograde but not the anterograde path (unidirectional block) 
in the bifurcating conduction pathway. The slowing conduction causes re-entry upset in the 
refractory tissue 18. The electrical uncoupling contributes to the conduction slowing and 
blocking in the initial phase of ischemia through the myocytes gap junctions 19. 
After the onset of coronary artery occlusion the ventricular arrhythmias appear in two 
distinct phases. The phase I arrhythmias appear in one single period in some species (for 
example rats), but in other animals, like dogs, it is divided into subcomponents as phase Ia 
and Ib arrhythmias  20, 21. The phase Ia arrhythmias occur between the 3 and 8 min of the 
ischemia, whereas the phase Ib arrhythmias appear approximately 15 min after the occlusion 
and they disappear 30 min after the onset of ischemia. During this 30 min period the ischemic 
changes can be considered reversible. 
1.2.1. Mechanisms of the Ia arrhythmias  
Soon after the onset of the coronary artery occlusion, the rapid changes in electrical 
membrane properties occur, due to the fast metabolic alterations. 23- 24. Thus the shift from 
aerobic to anaerobic metabolism produces both extracellular and intracellular drop in pH. 
Since the Na+/K+ exchanger requires ATP to maintain the normal ionic gradient the reduction 
in high energy phosphates causes a loss in intracellular K+. Because the extracellular K+ and 
H+ accumulation gradually decreases from the centre towards the border of the ischemic 
region 8- 9, the arrhythmias most likely appear in the border zone of the occluded area. 
Moreover, the intracellular acidosis increases the activity of Na+/H+ exchanger, which 
mechanism leads to the accumulation of intracellular Na+ 26. The Na+ influx leads to the influx 
of Ca2+, due to the reverse mode of Na+/Ca2+ exchanger. In the Ca2+-overloaded ischemic 
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myocytes uncontrolled activation of the contractile fibres occurs particularly during re-
oxygenation 27- 29. 
Phase Ia arrhythmia is preceded by the rapid evolution of delayed activation of 
myocytes within the ischemic sub-epicardium. When it exceeds 120-140 ms the localized re-
entry and ventricular arrhythmia can be observed 30. The resulting ventricular tachycardia is 
formed by large and highly unstable re-entry circuits with several millimetres inner circle 
length 30. The re-entry is confirmed to be a source of VF during the phase Ia arrhythmias 31. 
1.2.2. Mechanisms of phase Ib arrhythmias 
The second phase of early arrhythmias starts around the 15 min, and lasts until the 25-
30 min of the occlusion. The main factor of the appearance of Ib arrhythmias is the 
uncoupling of the cell-to-cell communication through gap junctions 32. This electrical 
uncoupling results in the slowing and blocking of conduction caused by the low pH level, the 
loss of intracellular K+ 30 and ATP as well as the increase in intracellular Ca2+ that cause the 
dephosphorylation of the channel proteins of the gap junctions 33. Moreover in smaller degree 
localized re-entry mechanisms also contribute to the appearance of phase Ib arrhythmias 30.  
However, if the coronary occlusion persists over a longer period the ischemia becomes 
irreversible and approximately 90 min after the occlusion the phase II arrhythmias occur, 
when a myocardial necrosis has started 22. 
1.2.3. Reperfusion injury 
The reperfusion results in a rapid restoration of action potential in the ischemic 
myocardium. However the returning electrical activity is not equally rapid for each cells. The 
significant inhomogeneity of electrical activation remains during the first 30 seconds of 
reperfusion within the ischemic area and at the border zone. Persistent membrane 
depolarization and gap junctional uncoupling could contribute to the occurrence of re-entrant 
arrhythmias during the early period of reperfusion 37. 
Restoration of blood supply to the myocardium results in substantial free radical 
production 34. These reactive oxygen and nitrogen species (ROS; NOS) generated during 
reperfusion play an essential role in the generation of the reperfusion arrhythmias.  
Numerous endogenous antioxidant mechanisms exist (such as superoxide dismutase – 
SOD, catalase, glutathione oxidase) in cells and organs that start to eliminate this reactive 
species during ischemia and reperfusion. However the prolonged ischemia and mainly a 
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following reperfusion provoke an excess of reactive species that the scavenger system cannot 
totally neutralize. The ROS may damage the sarcoplasmic reticulum (SR), causing Ca2+ 
release from the SR and an increase in the intracellular Ca2+  35. Later the high level of Ca2+ 
causes the decreasing of cardiac contractility because of the damage of contractile proteins 
and because of a reduced sensitivity to Ca2+. These processes might be involved in the 
contractile dysfunction of ischemic myocardium (myocardial stunning) 29. Moreover the 
superoxide radicals (O2.-) interact with NO 36 leading to the reduction of NO bioavailability 
and the generation of another reactive species, the peroxynitrite (ONOO.-). This inactivation 
of NO by ROS is a key element of the development of the endothelial dysfunction after 
reperfusion 38.  
The neutrophils from the blood contribute to the injury 29, damage the endothelium and 
also the myocardium. These cells accumulate in the reperfused myocardium and release their 
toxic agents such as oxidants, proteases and cytokines 39 -  41. 
1.3. Preconditioning as a possible mechanism to protect the heart against 
ischemia and reperfusion injury 
The injury of the prolonged coronary artery occlusion and subsequent reperfusion can 
be prevented by short periods of occlusion and reperfusion insults. This process stimulates 
those mechanisms, which can protect the myocardium against a subsequent ischemic insult. 
This adaptation of the heart is termed as ischemic preconditioning (IPC)1. The protection 
induced by PC is independent of the changes in collateral blood flow. A similar adaptation to 
ischemia and reperfusion can be achieved by other stimuli, like heat stress 41, stretching 43 and 
also by numerous pharmacological agents (pharmacological preconditioning). The rapid 
cardiac pacing is another way to create protection 3. Pacing induced short periods of 
tachycardia decreases the perfusion, but increases the energy and oxygen consumption. This 
hypoxic state of the myocardium, the increased heart rate and blood pressure can initiate the 
protection 44.  
The preconditioning stimulus can be evoked by a single period of treadmill exercise as 
well  45. The duration and the intensity of the physical exercise are important to induce the 
protection. The exercise elevates the heart rate, decreases the blood perfusion, increases the 
energy and oxygen supply, and remote effects may also play a role in this process. The 
exercise increases the heart vagal activity as well and preserves the baroreflex sensitivity 45. 
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During exercise there is a large vasodilatation of arterial vasculature in the heart and in the 
active skeletal muscle. This massive relaxation can be caused by NO. The NO is released 
from the endothelium from the effect of different hormones such as norepinephrine or the 
direct effect of shear stress 46. 
The protective mechanisms start immediately, regardless the preconditioning stimulus. 
The protection shows a biphasic pattern. The early protection is short lived, usually it 
disappears 1 or 2 h after the stimulus. However the beneficial effect can be seen again after 
12-24 h of the stimulus and remains for the next 2-3 days 47. In the early phase of 
preconditioning rapid post translational modifications of pre-existing proteins occur 48. The PC 
stimuli release endogenous substances (triggers) to start the PC process 49. These triggers 
activate those materials that prolong the processes (mediators). These mediators contribute to 
the signal transduction process between the triggers and the end-effectors. Parallel to the early 
protective mechanisms, the PC trigger induces those cellular mechanisms, which has effect on 
the late phase of PC. The important steps of this process are the de novo protein synthesis 48. 
1.3.1. Endogenous substrates as a trigger of preconditioning 
Numerous endogenous substrates were identified that may contribute as a trigger of 
the preconditioning, in tests conducted during the beneficial effect of PC. Some of these bind 
to the cell surface receptors like adenosine 50, bradykinin 51, opioid peptides 52, prostacyclin 53 
but the others induce their effect by non-receptor triggered manner such as NO 54 or other free 
radicals 55. It is hypothesized that these endogenous triggers act parallel to the early phase of 
preconditioning 56. This theory supposes a PC threshold that the triggers have to exceed. 
1.3.2. Signal transduction of early preconditioning 
The mediated signal of cell surface receptors may couple with inhibitory G-proteins 
(Gi) such as adenosine, bradykinin and opioid receptors. These proteins are connected to the 
phospholipase C and D (PLC and D). These enzymes catalyse the process to produce inositol 
triphosphates (I3P) and diacylglycerol (DAG). The DAG is the key component of the protein 
kinase C (PKC) activation, which has a central role in the infarct size limitation (as shown in 
rabbits) 57. Some authors proposed that the PKC activation and/or translocation might be an 
effect of oxygen radicals in PC 48. There is another cellular pathway that acts through the 
PI3K/AKT molecules to limit the infarct size 58. 
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The mitogen activated protein kinase (MAP) play a crucial role in the signalling 
pathways of PC as a mediator. These molecules are rapidly activated after the PC stimulus 
and they regulate cellular function by phosphorilation of proteins 48. The MAP kinase-
activated protein kinase 2 (MAPKAP 2) was identified to play an important role in the 
transcription of those proteins, which protect the myocytes in the delay phase of PC 48. 
1.3.3. Signal transduction of late preconditioning 
After the PC stimuli the cellular signal transduction processes activate gene 
transcription factors, which induce protein synthesis for the development of late PC. The PC 
stimulus activates the Nuclear Transcription Factor-κB (NF-κB) 48. The NF-κB in association 
with Signal Transducer and Activator of Transcription (STAT) molecules can induce the 
transcription of the several proteins, such as iNOS, COX-2, aldose reductase, MnSOD and 
heat shock proteins 59. 
1.3.4. End effectors of preconditioning 
The final mechanism of PC is still not very clear 48. Numerous theories were 
established and mechanisms were identified as the end-effectors of PC. The KATP channels 
were suggested as an end-effector in the PC processes. Two types of KATP channels were 
identified which are located in the heart: in the sarcolemmal and in the inner mitochondrial 
membrane. The investigations with their inhibitors show that both channel opening is 
necessary in the cardioprotection 59,  60.  
Opening of the sarcolemmal KATP channels shortens the AP duration 61 and prevent the 
Ca2+ overload in the myocyte by decreasing the open state probability of the inward Ca2+ 
channels 60. The L-type Ca2+ channel blockers inhibit the PC effect in human myocardium 62. It 
was hypostatised that either the mitochondrial Ca2+ handling or mitochondrial volume 
regulation help the preservation of mitochondria or the mitochondrial electron transport chain 
to preserve the ATP production during the injury by opening the mitochondrial KATP 
channels. 57 The mitochondrial protection increases the generation of ATP (protection of KATP 
channels), restores the dystrophin in the myocardium inert cell membrane. This restoration 
protects the sarcolemma and stabilizes the membrane against high permeability. 63  
Some other mechanisms were identified also as end-effectors in PC like the myocytes 
volume regulation by swelling activated chloride channels 64, actin filaments protection 
against cytosceletal disruption by activation of small heat shock protein 27 (HSP27) 65. 
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1.3.5. Possible mechanisms of early and delayed preconditioning against 
arrhythmias 
Numerous participants were identified in the cardioprotection when infarct size or 
stunning was examined, however only a few articles deal with participants in the 
antiarrhythmic signal transduction process. 
Numerous data were published about the adenosine A1 receptor involvement in early 
PC protection against infarct size, however the A1 receptor blocker was not effective against 
arrhythmias in dog models 66. Perhaps other adenosine receptors may contribute to the 
antiarrhythmic process 67. 
The stable analogue of prostacyclin (7-oxo-PGI2) can mimic an antiarrhythmic 
cardioprotective effect in the heart and this protection can be blocked by cyclo-oxigenase 
inhibitors 68,  69. Bradykinin B2 receptor was identified to have a role in the antiarrhythmic 
effect. The application of selective B2 antagonist (HOE 140, icatibant) showed that the 
receptor inhibition completely diminish the antiarrhythmic effect of PC stimulus (cardiac 
pacing), if the antagonist was given prior to the PC stimulation. However the inhibition just 
partially abolished the arrhythmias if it was given immediately after the pacing stimulus 70. 
This suggests that the bradykinin has a trigger role in this process. In contrast, in rats, it seems 
that the bradykinin acts in the later phase of the protection against arrhythmias rather than as a 
trigger 71. The role of opioid receptors has also been proven in PC protection against ischemia 
and reperfusion-induced injury, however their involvement in the antiarrhythmic protection 
seems controversial. The κ receptor has been found to have an antiarrhythmic effect in rats 72, 
whereas in swine this receptor activation is proarrhythmic 73. There is possible species 
specificity in the mechanisms of antiarrhythmic effect of PC 74.  
The NO, as a non-receptorial trigger of preconditioning also contributes to the 
antiarrhythmic effect of PC. Végh et al. (1992) showed, for the first time, that the L-arginine 
nitric oxide pathway has an involvement in the short periods of coronary artery occlusion 
induced antiarrhythmic effect in open chest dogs 54.  
The application of PKC blockers (satusporine and calphostine C) in rats, modify 
neither reperfusion arrhythmias nor the antiarrhythmic effect of PC 74. It seems that the role of 
PKC in cardioprotection remains controversial in rats, dogs and pigs 57. It seems that the 
PI3K/AKT pathways are not involved in the antiarrhythmic effect of ischemic 
preconditioning in isolated rat heart model 58.  
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In a dog model the treatment of mitochondrial KATP channel closer, (5-
hydroxydecanoate (5-HD)) inhibits the antiarrhythmic effect of ischemic PC. The KATP 
channel opener (diazoxide) inhibits the antiarrhythmic process if it was administrated before 
and after the PC stimulus, but it just weakens the effect if it was administrated after the PC 75. 
This suggests that this channel has a mediator role in the PC protection against arrythmias 
rather than as an end-effector. 
Treatment of selective cyclooxigenase 2 (COX-2) inhibitor (celecoxibe) was 
ineffective in the antiarrhythmic effect of exercise induced late phase of PC in dogs. It seems 
that the COX-2 derived prostacycline has no role in the antiarrhythmic effect of late PC 76.  
Numerous theories were proposed and molecules identified about the possible end-
effectors of PC in the heart. However the role of these molecules in the antiarrhythmic 
process still remains uncertain. 
1.3.6. Non receptorial triggers in cardioprotection 
Oxidative phosphorylation and mitochondrial respiration are porogressively uncoupled 
during hypoxia or ischemia/reperfusion 77. This uncoupling increases the production of free 
radicals: reactive oxygen and nitrogen species. The main sources of ROS in the heart are the 
endothelium, leukocytes and the myocardium itself. In cells, xanthine oxidase, NADPH 
oxidase and nitric oxide synthase (NOS) are responsible for the production of free 
radicals 37- 39. The myocardium has defence mechanisms against ROS such as superoxide 
dismutase, catalase, gluthation perixidase and endogenous antioxidants such as Vitamin E, 
ascorbin acid, cysteine, tioredoxin 79. It seems that free radicals not only damage the 
myocardium cells but also has a role in the PC processes. The ROS and the NO were 
identified as non receptorial triggers in the protection against the ischemia/reperfusion injury 
in the PC process 79. 
1.3.6.1. Role of ROS in the preconditioning process 
Numerous studies showed that ROS have a protective role in the delayed 
cardioprotection. ROS have a secondary role in the delayed protection, they open 
mitochondrial KATP channels 85. Moreover, some mediators (bradykinin, α-adrenoreceptor 
agonists, opioid peptides) also generate free radicals by opening these channels 86. The ROS 
activate the redox-sensitive molecules such as endogenous antioxidant enzymes like 
manganese-superoxide dismutase (MnSOD) 87 or thioredoxin. For example the thioredoxin 
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regulates the reduced state of the proteins, decreases the oxidative stress in cells. This 
molecule is down-regulated after ischemia and reperfusion, but up-regulated after IPC stimuli. 
In the PC heart it seems, that the redox-signal induced protein synthesis can contribute to cell 
survival in the myocites 48.  
However, the role of ROS regarding the early protection against arrhythmias still 
remains unclear. 
1.3.6.2. Nitric oxide as a trigger in antiarrhythmic process 
NO has a large vasodilatation effect with an extreme short half life. It is released from 
the endothelium by the effect of several endogenous molecules or physical stimuli. Three 
different isoforms of NO synthase (NOS) exist in the human body. Two out of three of these 
are present in the heart: endothelial NOS (eNOS) and inducible form of NOS (iNOS). NOS 
oxidize the guanidine group of L-arginine by consuming NADPH and molecular oxygen to 
produce NO. 
In dog and in rat in vivo models ischemic induced protective antiarrhythmic effect was 
abolished by using NOS inhibitors in the early phase of PC 54,  88. However this role of NO was 
not proved in the protection against infarct size, cell death and post-ischemic dysfunction 89.  
Numerous articles suggested that NO has a role in the late phase of PC protection 
against myocardial infarction or stunning. Exogenous NO is also sufficient to provoke the 
protective effect against stunning and infarction in rabbits and rodents 90. Their protective role 
against arrhythmias in late phase of protection still remains unclear.  
Babai et al. (2004) showed that a single period of treadmill exercise in conscious dogs 
suppressed the life-threatening ventricular arrhythmias that happened 24h after the treadmill 
exercise, when a major coronary artery was occluded, and then re-opened 45. This protection 
was abolished by the prior administration of aminoguanidine. NO involvement was 
suggested, since there was evidence of the upregulation of iNOS. The aminoguanidine is not a 
selective inhibitor of NOS enzymes. It powerfully inhibits a number of other enzymes such as 
histaminase, mitogene-activated proteine kinase, catalase, SOD and malondialdhyde 91 - 94. 
Moreover the iNOS upregulation by treadmill exercise does not necessary mean that NO is 
involved. Furthermore Bolli et al. have suggested the function of NO in the delayed PC: ‘NO 
mediated NO release’ 95. However there wasn’t any evidence whether the NO has a trigger and 
or mediator role in the exercise induced late PC protection against life-threatening 
arrhythmias 89. 
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2. Purpose of the research 
There were two main objectives of this research.  
1. To examine the role of reactive oxygen species in the early antiarrhythmic effect 
of ischemic preconditioning. In this case a highly diffusible and low molecular 
weight ROS scavenger N-2-mercaptopropionylglycine (MPG) 85- 87;  96- 97 was used. In 
this experiment PC was induced by two 5 min coronary artery occlusion 20 min prior 
to the 25 min occlusion of the LAD. 
In this topic the following questions were further investigated: 
- The demonstration of ROS formation in the ischemia induced preconditioning 
process, the initial and terminal time of the prolonged 25 min occlusion (test) 
period were planned. The lucigenin-induced chemiluminescence method was 
used to investigate the ROS formation in vivo. 
- In non PC dogs the arrhythmic effect of ROS was examined during myocardial 
ischemia. The possibilities to reduce the arrhythmias with an exogenous ROS 
scavenger were researched. 
- The MPG scavenging activity on phorbol 12-myristate 13-acetate (PMA) 
induced ROS generation was examined using the ferro-cytochrome-c reduction 
in vitro assay. This was implied by the fact that in vitro activation of canine 
peripheral mononuclear cells by PMA generates ROS formation.  
2. To obtain further evidence that nitric oxide is involved in the delayed phase of 
preconditioning induced by heavy physical exercise. In these experiments the role 
of NO was examined in the delayed antiarrhythmic effect of exercise, using  
- a non-selective NOS inhibitor ω-nitro-L-arginine-methyl-ester (L-NAME) and  
- a relatively selective iNOS inhibitor S-(2-aminoethyl)-methyl-isothiourea 
(AEST). 
L-NAME was given prior to physical induction. AEST was administered 
immediately before the 25 minute test occlusion period. 
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3. Materials & Methods 
3.1. Animals 
Adult, mongrel dogs of either sex were used, with a body weight between 16 and 41 kg 
(mean 26.3 ± 1 kg) in the early and 18 and 35 kg (mean 26 ± 1) in the delayed PC 
experiments. The origin, maintenance, care, handling and treatments of these dogs complied 
with the requirements of Hungarian law (XXVIII, chapter IV, paragraph 31) and those of the 
European Commission regarding large experimental animals, which conforms to the Guide 
for the Care and Use of Laboratory Animals (86/609/ECC) published by the US National 
institutes of Health (NIH Publication no. 85-23; revised 1996). 
3.2. Evaluation of the role of ROS in the early protective effects of 
preconditioning 
3.2.1. Surgical preparation 
Under light anaesthesia (Sigma, 20 mg kg-1 intravenous sodium pentobarbitone) the 
right femoral artery (for the measurement of systolic, diastolic blood pressure - SABP, DABP, 
and heart rate - HR) was catheterised. The right femoral vein was also catheterized through 
which a mixture of chloralose (60 mg kg-1) and urethane (200 mg kg-1) was administered to 
maintain anaesthesia. The left common carotid artery was prepared and a catheter was 
inserted into the left ventricle cavity to measure the left ventricle systolic (LVSP) and end-
diastolic (LVEDP) pressures.  
The dogs were ventilated with room air, and blood gases as well as pH were monitored 
at various time intervals, and kept within the normal range 96. Body temperature was recorded 
from the rectum and was maintained at 37 ± 0.5 oC.  
A thoracotomy was performed at the left fifth intercostal space and the pericardium was 
excised. The main anterior descending branch of the left coronary artery (LAD) was prepared 
for occlusion just proximal to the first main diagonal branch. A side branch of this artery was 
also catheterised for the local, intracoronary administration of saline or of N-2-
mercaptopropionylglycine (MPG). The circumflex branch of the left coronary artery (LCX) 
was prepared and an electromagnetic flow probe (diameter 4 mm) was positioned on the 
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coronary artery. Myocardial blood flow (MBF) was measured in ml.min-1 using a blood flow-
meter (Spectramed, Hugo Sacs Electronics, Germany). 
A composite electrode 91,  96 was sutured on the surface of the potentially ischemic area. 
This was used to assess changes in the degree of inhomogeneity of electrical activation. This 
electrode gives a summarised recording of R-waves from 30 epicardial measuring points. In 
the normal, adequately perfused myocardium, all sites are activated almost simultaneously 
resulting in a single large spike. Under conditions of ischemia, fractionation of the 
summarised R-waves occurs, indicating that adjacent fibres are not simultaneously activated 
because of conduction inhomogeneity. This is expressed as the greatest delay in activation (in 
ms) within the ischemic area. This electrode also contains four unipolar leads by which 
epicardial ST-segment changes were measured. The parameters were recorded on a Graphtec 
Thermal Array Recorder (Hugo Sachs Electronics, Germany) and data were also analysed off-
line by the Advanced CODAS Analysing System  
3.2.2. Experimental protocol 
The experimental protocol is shown in Figure 1. Four groups of dogs were used. Each 
animal was subjected to a 25 minute LAD occlusion followed by a rapid reperfusion. Control 
dogs (C; n = 11) and dogs in the MPG control group (C+MPG; n=9) were given either normal 
saline or MPG, respectively, by intracoronary infusion for 1h prior to the occlusion The dose 
of MPG was 0.15 mg kg-1min-1 (the total dose: 9 mg kg-1 ), which roughly equates to an 
intravenous dose of 90 mg kg-1;  99 that has been used in previous studies 83,  96,  97. Twenty dogs 
were preconditioned as previously described 98, and 20 min later these dogs were subjected to 
a 25 minute LAD occlusion, followed by a rapid reperfusion. In one group of these PC dogs 
MPG (PC+MPG; n = 10)) was administered by the same route and dose as described above. 
The MPG infusion was started 10 min prior to the first PC occlusion and maintained 
throughout the whole preconditioning procedure (Figure 1). 
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Figure 1. Experimental protocol to examine the role of ROS in the early effect of PC. 
Before occlusion every group was administered saline (0.5 ml min-1) or MPG (0.15 mg kg-
1
 min-1) by intracoronary infusion over 1 h. The animals then underwent a 25 min LAD 
occlusion followed by a rapid reperfusion. The groups were preconditioned by two 5 min 
LAD occlusion. In four preconditioned dogs blood samples (BS) were taken from the 
coronary sinus for the determination of free radical production at various times of the 
experiment; as shown in Figure 7. 
In order to determine ROS formation during PCs and the effectiveness of MPG to 
scavenge ROS, four additional dogs (not shown in Figure 1.) were preconditioned in the 
absence and later in the presence of MPG as shown in Figure 7. Two hours after the second 
PC stimulus these dogs were treated with MPG. This two hour interval is sufficient enough 
for the previous preconditioning induced protective effect to disappear 96,  98. Twenty minutes 
after the last PC stimulus these dogs were also subjected to a 25 minute occlusion. In this self-
control experiment the actual ROS formation was measured at different times (see Figure 7). 
The ROS were determined from blood samples (BS1-BS9; see details in chapter 3.2.4). 
3.2.3. In vitro studies for the determination of superoxide anion generation by 
canine leucocytes 
Superoxide anion generation was assayed by measuring the superoxide-dependent 
reduction of ferro-cytochrome-c, as described by Guarnieri and colleagues 102. 2 mLs of blood 
were collected from the control dogs in tubes containing 100 mM EDTA and 100 mM 
dextran. PMNs were isolated from blood by Ficoll-Hypaque gradient, then centrifuged at 
200 g for 20 min at room temperature. After the centrifugation it was re-suspended in 40 µM 
ferricytochrome-c containing Dulbecco phosphate-buffered saline (DPBS) solution (1.5 × 106 
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cells/sample/cuvette). The cells were allowed to equilibrate for 2 minutes at 37 0C, and then 
stimulated with 0.3 µM phorbol myristate acetate (PMA). Superoxide radical production was 
recorded graphically as the increase in absorbance at 550 nm. The effect of increasing doses 
of MPG (1, 5, 10, 20 mM) was expressed as the percent change in the linear rate of 
ferricytochrom-c reduction, using a molar absorption coefficient of 19.1×103 M-1 cm-1. 
3.2.4. Determination of ROS production during preconditioning absence and 
presence of MPG 
In the four dogs which were subjected to preconditioning in the absence and then, 2 
hours later, in the presence of MPG, the amount of superoxide was detected from their blood 
at different times (see Figure 7). The free radical production was examined with the lucigenin-
enhanced chemiluminescence (CL) assay 101. At each time point two ml blood samples were 
collected from the coronary sinus in EDTA containing micro-tubes. The samples were 
centrifuged for 5 min, at 200 g at room temperature. Plasma aliquots (100 µl) were added to 
250 µM lucigenin in DPBS solution (final volume 1 ml). After a 2 minute equilibration period 
in darkness, measurements were commenced. CL was measured with a liquid scintillation 
counter (Packard Tri-Carb 2100 Model) with a single photomultiplier tube positioned in out-
of-coincidence mode. CL was detected in the presence of nitro-blue-tetrazolium (NBT; 200 
µM). NBT-inhibited CL was assessed as an index of superoxide generation. Results were 
expressed in counts min-1mg-1 protein in 100 µL plasma. 
3.3. Examination of the role of NO in delayed preconditioning induced 
by physical exercise 
3.3.1. Surgical preparation 
Under light pentobarbitone anaesthesia (sodium pentobarbitone, Sigma, 30 mg kg-1 
i.v.), heparinised, saline-filled polyethylene catheters were inserted into the left external 
jugular vein for drug administration, and, in some dogs (group 2; see below) into the left 
carotid artery for the measurement of arterial blood pressure. Each day the catheters in these 
dogs were flushed with heparinised saline. The dogs were then allowed to adapt to laboratory 
conditions for a week. During this period the dogs were transported to the laboratory and were 
either made to stand on the treadmill or made to exercise.  
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24 hours later the dogs were given intramuscular ketamine (50 mg kg-1, i.m; Richter) 
and then anaesthetised with a mixture of α-chloralose and urethane (80 and 200 mg kg-1 i.v., 
respectively; Sigma) and were prepared for the test occlusion. The catheters insertion, 
thoracotomy and the heart preparation for the experiments were similar than previously 
described in Chapter 3.2.1.  
3.3.2. Exercise protocol 
The exercise protocol is illustrated in Figure 2. The dogs underwent a surgical 
procedure as described in Chapter 3.2.1. After one week of adaptation the dogs (n=34) were 
subjected to a total exercise period of 21 minutes. The slope and the speed of the treadmill 
were increased every 3 min reaching the maximum during the final 3 min period 45 (see: 
Figure 2.). Heart rate (HR) was measured during the exercise by a chest lead 
electrocardiogram. Data were collected by a computer assisted system and analyzed with the 
Advanced CODAS Analyzing System using the Windaq Waveform Browser playback and 
analysing software (DATAQ Instruments, USA). 24 hours later these dogs were anaesthetised 
as described above and underwent a test occlusion (see: Chapter 3.2.1 and 3.3.1.).  
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Figure 2. Exercise protocol. The dogs were run for 21 min on treadmill. The slope and the 
speed was increased every 3 min starting from 6.4 km h−1 and a 0% grade during the first 3 
min and finishing with a speed of 13 km h−1 and a 13.5% slope during the last 3 min period 45.  
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3.3.3. Experimental protocol 
The experimental protocol is illustrated in Figure 3. A total of 65 dogs were used in 
the study. The dogs were accustomed to the laboratory conditions for 1week by standing on 
the treadmill. After this adaptation, these dogs were anaesthetised, as described above, and 
subjected to a 25 minute occlusion of the LAD followed by a rapid re-opening of the occluded 
artery. Thirteen dogs served as controls; i.e. after surgery and the adaptation period these dogs 
were subjected to a 25 min occlusion and reperfusion insult (Figure 3). Nine out of the total 
65 dogs (group 2; Figure 3) the specific, but non-selective, NOS inhibitor Nω-nitro-L-
arginine-methyl-ester (L-NAME, Sigma) was given intravenously in a dose of 10 mg kg-1, 
24 h prior to the coronary artery occlusion. In a previous study this dose of L-NAME has been 
shown to abolish the antiarrhythmic effects of ischemic preconditioning 54. In another group of 
nine control dogs (group 3; Figure 3), S-(2-aminoethyl)-isothiourea (AEST, Tocris), a 
selective inhibitor of the inducible NOS enzyme (iNOS), was administered in intravenous 
infusion over a 70 minute period (total dose of 2 mg kg-1). The infusion was stopped 20 
minutes prior to the coronary artery occlusion. This dose of AEST was similar to that used to 
inhibit the delayed antiarrhythmic effects of cardiac pacing 103. 
Thirty four dogs were subjected to the exercise protocol 24h prior to the coronary 
artery occlusion. Eleven of these dogs (group 5; Figure 3) were treated with L-NAME (10 mg 
kg-1) 5 minutes prior to the exercise. Of the remaining exercised dogs ten were given AEST 
intravenously (group 6; Figure 3) in a dose and time outlined above. The results were 
compared to those obtained from a group of thirteen exercised dogs given saline 
intravenously 20 minutes prior to the occlusion (group 4; Figure 3). 
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Figure 3. Experimental protocol for the investigation of the role of NO in the delayed 
antiarrhythmic protection induced by treadmill exercise, using inhibitors of NOS. The number 
of dogs in each of six groups is given in parenthesis. 
3.4. Investigated parameters in both experiment 
In the right femoral artery the systolic (SABP), and the diastolic blood pressure (DABP) 
and also the heart rate (HR) were measured. The mean arterial blood pressure (MABP) was 
calculated from the SABP and DABP. Left ventricular systolic (LVSP) and end diastolic 
pressure (LVEDP) were measured from a catheter inserted into the left common carotid 
artery. The maximum and the minimum of the first derivate of LVP over time (LVdP/dt) were 
calculated from these parameters. The coronary blood flow was measured in the left 
circumflex coronary artery using an electromagnetic flow probe (Spectramed, Hugo Sachs 
Electronics, Germany) to monitor the compensatory coronary blood flow, when a 
myocardium oxygen consumption increased or when the inhibitors were used. The principle 
of the measuring is the electro-magnetic force induction in the signal electrode circuit when 
the flow-meter probe magnet is energized by an alternating current deriving from Faraday’s 
law of electromagnetic induction 104. 
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Ventricular arrhythmias during a 25 min (LAD) coronary artery occlusion and 
following reperfusion were assessed as outlined in the ’Lambeth Conventions’ 105 and 
modified as previously described 91,  96. During occlusion we assessed the total number of 
ventricular ectopic (premature) beats (VPB’s) and the incidence and number of episodes of 
ventricular tachycardia (VT; defined as a run of four or more VPB’s at a rate faster than the 
resting sinus rate). The incidence of ventricular fibrillation (VF) during both occlusion and 
reperfusion were also determined. Those dogs were considers survivors whose heart beat was 
in sinus rhythm for 10 minutes after the combined ischemia-reperfusion insult.  
A composite electrode was used to assess changes in the degree of inhomogeneity of 
electrical activation and recorded epicardial electrocardiograms (for changes ST segment).  
Risk area was assessed at the end of each experiment by injecting patent blue V dye into 
the LAD at a pressure not greater than the systolic arterial pressure in that animal. It was 
defined as the percentage area of the left ventricular wall together with the septum served by 
the occluded artery 91,  118. 
3.5. Statistical evaluation 
All data were expressed as means ± s.e.m. and the differences between groups were 
compared by Student’s t test analysis or ANOVA. A two-way, repeated measured ANOVA 
was undertaken to determine whether or not there were significant differences of the ST-
segment elevation and a degree of inhomogeneity between the groups. The problem of 
multiplicity was solved by Bonferroni correction. Ventricular premature beats were compared 
using the Mann-Whitney Rank Sum test and the incidences of VT and VF between the groups 
using the Fisher Exact test. Differences between the groups were considered significant when 
P < 0.05.  
4. Results 
4.1. Evaluation of the role of ROS in the early protective effect of 
preconditioning 
4.1.1. Haemodynamic effects of MPG and coronary artery occlusion 
These are illustrated in Table 1. Intracoronary infusion of MPG resulted in significant 
reductions in arterial blood pressure and LVdP/dt, but these values returned to normal by the 
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time of the onset of the coronary artery occlusion. The infusion of saline for the same period 
of time had no significant haemodynamic effects. 
The coronary occlusion induced a marked fall in arterial blood pressure (SABP and 
DABP) and increased the LVEDP, without substantially modifying the HR. These 
haemodynamic changes were similar in the control (C) and in the MPG treated control (C + 
MPG) dogs. In contrast, the occlusion-induced haemodynamic alterations were less 
pronounced in dogs subjected to preconditioning (Table 1). Administration of MPG in PC 
dogs reversed most of these PC-induced haemodynamic changes (Table 1).  
When the LAD coronary artery was occluded there was an immediate and sustained 
increase in blood flow in the adjacent (LCX) coronary artery. This compensatory coronary 
blood flow increase was not affected by the administration of MPG (Table 2). 
4.1.2. Ventricular arrhythmias during occlusion 
The distribution of ventricular premature beats over a 25 minute occlusion period in 
the four groups is illustrated in Figure 4. In control dogs following the occlusion the ectopic 
activity appeared in two well differentiated phases (1a and 1b). Compared to the controls, in 
dogs subjected to preconditioning there were only a few VPBs over the entire 25 minute 
occlusion (377 ± 78 vs 86 ± 34; P < 0.05) and this arrhythmia suppressing effect of PC was 
not significantly modified by MPG (VPBs: 111 ± 39). MPG itself, administered in control 
animals suppressed the number of the ectopic beats only during phase Ia, but the total number 
of VPBs was not significantly different from the controls (377 ± 78 vs. 244 ± 56; p = 0.165). 
Similarly, the incidence and the number of episodes of VT were less in the two 
preconditioned groups, regardless whether MPG was present or not. Thus, VT occurred in 
60% of PC dogs and 25% of the PC+MPG treated dogs (2.0±0.7 and 1.2±0.9 episodes of VT) 
compared to 91% and 89% in the C and C + MPG groups (13.6 ± 4.5 and 8.6 ± 2.5 VT 
episodes respectively; all P < 0.05). MPG itself reduced VPBs during phase Ia, but not in Ib 
phase arrhythmias. However the total numbers of arrhythmias over the entire occlusion period 
was not significantly different from the controls (p = 0.165). 
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Table 1. Haemodynamic changes following saline or MPG infusion and during coronary 
artery occlusion 
 
Baseline 
Max change 
during saline or 
MPG infusion 
Pre occlusion  
value 
Max change 
during occlusion 
Control             
SABP 115 ± 4 -5 ± 0 114 ± 5 -16 ± 4” 
DABP 80 ± 4 -3 ± 3 77 ± 3 -10 ± 1” 
MABP 92 ± 4 -3 ± 2 89 ± 4 -12 ± 2” 
LVEDP 3.5 ± 0.5 0 ± 0 3.8 ± 0.4 9.8 ± 1.1” 
+dP/dt 1619 ± 180 -44 ± 44 1610 ± 183 -344 ± 8.3” 
-dP/dt 1907 ± 311 169 ± 7 1968 ± 302 -375 ± 5.5” 
HR 160 ± 5 2 ± 0 160 ± 5 3 ± 1 
             
C + MPG             
SABP 133 ± 4 -17 ± 3* 129 ± 6 -15 ± 4” 
DABP 86 ± 5 -18 ± 3* 81 ± 6 -11 ± 2” 
MABP 102 ± 4 -17 ± 3* 97 ± 5 -12 ± 3” 
LVEDP 2.5 ± 0.5 0 ± 0.8 3.5 ± 0.7 5.7 ± 1.1” # 
+dP/dt 1747 ± 115 -176 ± 68* 1754 ± 134 -261 ± 135 
-dP/dt 1743 ± 153 -289 ± 70* 1580 ± 152 -279 ± 47” 
HR 142 ± 5 2 ± 3 144 ± 7 1 ± 1 
             
PC             
SABP 121 ± 2 0 ± 2 123 ± 3 -5 ± 1” # 
DABP 77 ± 42 1 ± 2 77 ± 5 -9 ± 1 
MABP 92 ± 42 2 ± 1 94 ± 4 -8 ± 1” 
LVEDP 3.9 ± 0.5 0.3 ± 0.2 4.1 ± 0.6 5.5 ± 1” # 
+dP/dt 1406 ± 115 49 ± 36 1646 ± 144 -294 ± 51” 
-dP/dt 1747 ± 148 30 ± 30 1757 ± 186 -150 ± 134 
HR 142 ± 6 0 ± 0 138 ± 5 1 ± 1 
             
PC+MPG             
SABP 130 ± 5 -17 ± 2* 124 ± 4 -12 ± 2” 
DABP 92 ± 6 -16 ± 2* 85 ± 5 -13 ± 3” 
MABP 104 ± 5 -16 ± 2* 98 ± 5 -12 ± 3” 
LVEDP 4.7 ± 0.4 -0.2 ± 0.4 4.2 ± 0.5 5.3 ± 0.6” # 
+dP/dt 1478 ± 84 -118 ± 28* 1465 ± 92 -306 ± 59” 
-dP/dt 1640 ± 173 -151 ± 44 1685 ± 167 -400 ± 88” 
HR 143 ± 5 1 ± 2 144 ± 6 6 ± 3 
Values are mean ± s.e.m. Abbreviations are seen in the methods section. * P<0.05 cp. 
baseline; “ P<0.05 cp. pre occlusion value; # P<0.05 cp. control group 
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Table 2. Changes in LCX artery blood flow (mean; ml.min-1) during occlusions of the LAD coronary 
artery (‘compensatory coronary vasodilatation’) 
 Preconditioning Prolonged occlusion 
 Occlusion 1 Occlusion 2  
 Pre Post Pre Post Pre Post 
Control (saline)     47.9 ± 5.2 60.2 ± 8.7 
Control (MPG)     53.9 ± 2.9 68.7 ± 4.5* 
Preconditioned 
(saline) 51.0 ± 6.5 59.6 ± 6.8* 54.4 ± 5.9 62.7 ± 5.8* 53.6 ± 5.9 64.5 ± 7.4* 
Preconditioned 
(MPG) 54.4 ± 5.5 59.9 ± 6.5* 51.3 ± 5.0 59.9 ± 6.4* 52.6 ± 5.0 66.1 ± 7.2* 
Values as mean ± s.e. mean of 10-11 observations. *: P<0.05 compared with baseline. 
The incidence of VF during occlusion and reperfusion, as well as survival from the 
combined ischemia/reperfusion insult is illustrated in Figure 5. In control dogs there was an 
82% incidence of VF during occlusion and those dogs that survived the ischemic period 
fibrillated on reperfusion, thus in this group no dog survived the ischemia/reperfusion insult. 
In contrast, no preconditioned dog fibrillated during the occlusion period, whether or not they 
were given MPG, but there was a high incidence of fibrillation on reperfusion. Survival from 
the combined ischaemia/reperfusion insult was 40% in PC dogs and 29 % in the PC + MPG 
group.  
4.1.3. Severity of ischemia during PC and following coronary artery occlusion 
The severity of ischemia was assessed by measuring changes in epicardial ST-segment 
(Figure 6A) and in the degree of inhomogeneity of electrical activation (Figure 6B). In control 
dogs following coronary artery occlusion the ST-segment rapidly elevated during the initial 5 
minute of the occlusion, and this was maintained throughout the whole ischaemic period 
(Figure 6/A). MPG given to non-preconditioned dogs did not modify these ST-segment 
changes. Preconditioning significantly reduced this index of ischemia severity, which effect 
was not substantially modified by MPG during the early period of the ischemia. However, in 
the later course of the occlusion (from 8-10 minutes on) the change of the epicardial ST-
segment in PC dogs treated with MPG, were similar to the control group. Changes in the 
electrical activation are shown in Figure 6/B. In control dogs the degree of inhomogeneity 
within the ischemic myocardium was markedly increased following LAD occlusion, but this 
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increase was significantly less pronounced in the PC animals. Again, MPG in PC dogs 
increased this index of ischemia severity only during the later period of the occlusion. 
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Figure 4. The distribution of VPBs during a 25 min occlusion of the LAD. In the control 
group there was a great number of VPBs which appeared in two distinct phases (phase Ia and 
Ib). The PC procedure significantly reduced the number of ectopic beats, and this effect was 
not substantially modified by the administration of MPG. The ROS scavenger MPG in control 
dogs attenuated only the phase Ia arrhythmias. 
4.1.4. Area at risk 
There were no significant differences in the ‘area at risk’ between the four groups. 
These were 32.2 ± 1.3 % in the saline controls, 32.4 ± 1.1 % in the controls given MPG, 31.4 
± 1.1 % in the preconditioned group and 34.2 ± 1.4 % in the preconditioned dogs also given 
MPG. 
 
 - 31 - 
0
10
20
30
40
50
60
70
80
90
100
C C
+
M
PG
PC PC
+
M
PG
C C
+
M
PG
PC PC
+
M
PG
%
 
o
fV
F 
a
n
d
Su
rv
iv
a
l
VF Survival
*
**
C C
+
M
PG
PC PC
+
M
PG
C C
+
M
PG
PC PC
+
M
PG
%
 
o
fV
F 
a
n
d
Su
rv
iv
a
l
 
Figure 5. The incidence of ventricular fibrillation and survival from the combined 
occlusion/reperfusion insult. In the control group there was a high incidence of VF (87 %) 
during the occlusion period, and no dog survived the reperfusion. In contrast, in the PC dogs 
no VF occurred during the occlusion and 40% of the animals survived reperfusion. The 
administration of MPG did not modify the severity of arrhythmias either in the control or the 
PC groups *:p<0.05 vs. control 
4.1.5. Effect of MPG on free radical production by canine leucocytes 
MPG concentrations smaller than 1 mM did not affect the ferricytochrome-c 
reduction. The higher concentrations of MPG (5, 10 and 20 mM) significantly decreased this 
reaction by 13%, 54% and 96 % respectively. 
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Figure 6. Changes in ischemia severity during a 25 min occlusion of the LAD. Compared to 
controls, PC significantly reduced both the elevation of epicardial ST-segment (A) and the 
increase of the degree of inhomogeneity (B). These indices of ischemia severity in the control 
dogs were not modified by MPG, whereas in the PC dogs MPG reversed the effect of PC 
during the later course of the occlusion.  Values are means ± s.e.m. *:p<0.05 vs. control. 
3.1.7 Effect of MPG on ROS production before, during and after the PC procedure 
In four dogs subjected to preconditioning in the presence and in the absence of MPG, 
free radical formation was detected by the lucigenin-enhanced chemiluminescence assay. The 
results are shown in Figure 7. There was no detectable free radical formation following the 
first preconditioning occlusion. However, 20 minutes later, when the second PC occlusion 
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was released there was a significant, around three-fold, increase in ROS formation. Two hours 
later, when the preconditioning procedure was repeated, in the presence of MPG, no 
detectable ROS production could be observed either after preconditioning or following the 
prolonged occlusion. 
BS1: Baseline
BS2: 1. PC occlusion following reperfusion
BS3: 2. PC occlusion following reperfusion
BS4: Baseline
BS5: 5 min of MPG administration
BS6: 1. PC occlusion following reperfusion
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Figure 7 Free radical formation in PC dogs in the presence and in the absence of MPG. The 
blood samples (BS1-9) were collected at various times from the coronary sinus of the dogs. 
The burst of chemiluminescence activity were observed only after the second 5 min PC 
stimulus. This elevation was diminished by the applied MPG. *:p<0.05 vs. baseline (BS1). 
4.2. Examination of the role of NO in delayed cardioprotection induced 
by physical exercise 
4.2.1. Heart rate changes during exercise 
Exercising dogs on the treadmill for 21 min resulted in sustained increase in heart rate 
similar to those obtained using the same protocol in the previous study 45 (e.g. from 109±9 to 
212±20 beats min-1 at the end of the exercise period; P <0.01 of dogs in Exercise group 4). 
The resting heart rate, before the exercise in those dogs that had been given L-NAME (group 
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5) was significantly lower (88±4 beats min-1; P <0.01) than the normal HR (119±7 
beats min-1). This was presumably because of the marked elevation in arterial blood pressure 
that resulted from L-NAME administration (increase from 153±9 mmHg (systolic) and 101±3 
mmHg (diastolic) to 163±5 mmHg and 122±4 mmHg respectively; P <0.05) evoked a reflex 
mediated reduction in HR. Despite this the increase in heart rate during exercise was the same 
in all exercised groups. 
4.2.2. Haemodynamic effects of NOS inhibition and of coronary artery occlusion  
Administration of L-NAME resulted in the increase in arterial blood pressure (DABP: 
from 101±3 to 122±4 mmHg, MABP: from 118±4 to 135±4 mmHg; P < 0.05) and a 
significant decrease in HR (from 107±8 to 78±6 beats min-1; P<0.05) Twenty-four hours later, 
these acute haemodynamic changes of L-NAME have already disappeared, only the decreased 
HR remained. 
In dogs, exercised 24h previously (but not in non-exercised dogs) the infusion of 
AEST prior to coronary artery occlusion increased the arterial blood pressure from 119 ± 5 
mmHg (systolic) and 80 ± 6 mmHg (diastolic) to 127 ± 7 and 87 ± 4 mmHg respectively. 
There were no significant changes in any other haemodynamic parameters. This change in 
arterial blood pressure (+7 ± 3 mmHg) was significantly greater than in non-exercised dogs 
that were given AEST (-5 ± 5 mmHg; P < 0.05). 
4.2.3. Haemodynamic effect of coronary artery occlusion 
These are summarised in Table 3. The haemodynamic parameters measured at rest 
were similar in each of the six groups. The mean arterial blood pressure in the six groups was 
between 93 ± 3 and 105 ± 11 mmHg, the heart rate was between 145 ± 7 and 154 ± 5 beats 
min-1, and the LVEDP was between 3.2 ± 0.5 and 4.3 ± 0.4 mmHg. The only significant 
difference was that the heart rate in those (groups 2 and 5) dogs that had been given L-NAME 
on the previous day was still lower that in the other groups (118 ± 5 beats min-1 in the group 2 
dogs and 122 ± 5 beats min-1 in the group 5 dogs; P < 0.05 compared to the dogs not given L-
NAME). 
The haemodynamic changes following coronary artery occlusion were similar to those 
described in detail previously 91,  98. There were slight, but significant (P < 0.05) decreases in 
arterial blood pressure (between 7 to 16 mmHg), and increases in heart rate (less than 10 beats 
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min-1) in each group following occlusion. The only significant difference between the six 
groups in the haemodynamic response to coronary artery occlusion was in LVEDP. This was 
more pronounced in control dogs (group 1; increase from 4.6 ± 0.5 to 16.8 ± 2.1 mmHg at 10 
min; P < 0.05) than in the exercised dogs (group 4; increase from 3.4 ± 0.7 to 5.3 ± 1.1 
mmHg; ns but P < 0.05 cp to controls). The increases in LVEDP were again more pronounced 
in exercised dogs given either NOS inhibitor ((e.g. 3.6 ± 0.5 to 9.9 ± 0.6 mmHg in the L-
NAME (group 5) dogs and from 3.2 ± 0.5 to 9.9 ± 1.1 mmHg in the (group 6) dogs that had 
been given AEST (both P < 0.05); see Table 3).  
Table 3. Haemodynamic effect of coronary artery occlusion in control dogs subjected to exercise 24 h previously; effect of 
L-NAME and AEST. 
 Mean arterial blood 
pressure (mmHg) 
Heart rate 
(beats ⋅ min-1) 
LVEDP  
(mmHg) 
LV dP/dtmax  
(mmHg ⋅ s-1) 
 Pre Post Pre Post Pre Post Pre Post 
Group 1  
(n = 13) 97 ± 7 90 ± 3* 151 ±5 154 ± 6 4.6 ± 1 16.8 ± 2.1* 3521 ± 187 3001 ± 213* 
Group 2  
(n = 9) 94 ± 3 86 ± 3* 118 ± 3
+
 120 ±5+ 3.9 ± 1 15.3 ± 1.4* 2529 ± 157 3110 ± 188* 
Group 3  
(n = 9) 105 ± 11 90 ± 5* 154 ± 5 158 ± 3 4.3 ± 1 14.6 ± 1.3* 3398 ± 239 2829 ± 162* 
Group 4  
(n = 13) 105 ± 2 97 ± 3* 152 ± 7 157 ± 5 3.4 ± 1 8.3 ± 1*
+
 3338 ± 245 2921 ± 177* 
Group 5  
(n = 11) 93 ± 3 85 ± 3* 123 ± 5
+
 133 ± 5+ 3.6 ± 1 12.5 ± 0.6* 3464 ± 226 3145 ± 98* 
Group 6  
(n = 10) 97 ± 4 90 ± 3* 145 ± 7 148 ±3 3.2 ± 1 13.4 ± 0.8* 3156 ± 249 2687 ± 162* 
Values are means ± s.e.m before (pre) and after (post) coronary artery occlusion. *: p < 0.05 compared to pre occlusion 
value. +: p < 0.05 compared to control group. 
 
4.2.4. Ventricular arrhythmias during coronary artery occlusion 
The results are shown in Figure 8. In control dogs occlusion of the LAD resulted in 
many ventricular premature beats (VPBs: 311.1 ± 81.9), a high incidence (85%) and number 
of VT episodes (15.5 ± 6.3 episodes per dog). Six dogs (46%) out of the 13 from the control 
group fibrillated during occlusion; most of the VF occurred during phase Ib (i.e. between 14 
and 18 min of the ischemia), and no control dog survived the reperfusion. In contrast, in the 
exercised dogs, the number of VPBs (103.1 ± 30.2), the incidence (54%) and number of 
episodes of VT (2.2 ± 1.0) were significantly reduced compared with control group. Only one 
of these dogs exhibited VF (8%) during the occlusion (at the 14 min of the ischemic period) 
and 5 dogs out of 12 fibrillated during reperfusion. Thus 54% of these dogs survived 
reperfusion (p < 0.05 compared to controls). This protection was abolished by both L-NAME 
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and AEST (Figure 8). Only three of the 21 exercised dogs given a NOS inhibitor survived 
reperfusion (P < 0.05) compared to exercised dogs not given the inhibitor. Neither L-NAME 
nor AEST significantly influenced occlusion or reperfusion-induced arrhythmias in non-
exercised dogs (data are not shown). 
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Figure 8. The severity of arrhythmias (VPBs, VF and survival) following a 25 min occlusion 
and reperfusion insult. Exercise, 24 h prior to coronary artery occlusion and reperfusion 
significantly reduced the severity of arrhythmia. This effect was largely reversed by NOS 
inhibitors administered either prior to the exercise stimulus (L-NAME) or, on the following 
day, before coronary artery occlusion (AEST). *:p < 0.05 vs. control. 
4.2.5. Changes in the degree of inhomogeneity of electrical activation during LAD 
occlusion 
These are shown in Figure 9. The degree of inhomogeneity of electrical activation was 
significantly increased during occlusion. This effect was less pronounced in dogs subjected to 
exercise, 24h previously. The two NOS inhibitors reversed the effect of the exercise; in these 
dogs the degree of inhomogeneity of electrical activation was similar to that in the control 
group. 
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Figure 9. Changes in the degree of inhomogeneity of electrical activation within the ischemic 
area during a 25 min occlusion of the LAD. In dogs subjected to exercise 24 h previously the 
inhomogeneity of electrical activation was significantly reduced, but it increased again 
following inhibition of NO formation. *:p < 0.05 vs. control group; #: p < 0.05 vs. exercise 
alone. 
4.2.6. Area at risk 
There were no significant differences in the area at risk between any of the groups. These 
were 32 ± 1 % in the controls (group 1), 34 ± 2 % in the exercised dogs (group 4) and 33 ± 1 
% and 35 ± 1 % in the exercised dogs given L-NAME and AEST (groups 5 and 6). Neither L-
NAME nor AEST modified the area at risk in non-exercised dogs (groups 2 and 3; 31 ± 2 and 
34 ± 5 % respectively). 
5. Discussion 
5.1. The role of ROS in the early antiarrhythmic effect of 
preconditioning 
In canine 69,  107, as in other species 107,  108,  100, the severity of the ventricular arrhythmias is 
reduced when a prolonged period of occlusion is preceded by one or more brief 
(preconditioning) ischemia and reperfusion insults. This pronounced antiarrhythmic effect of 
ischemic preconditioning was clearly demonstrated in this study. None of the preconditioned 
dogs fibrillated during the occlusion compared with a high incidence (82%) in the control 
group. The number of VPBs and VT episodes were also much less in dogs that underwent a 
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PC procedure. Moreover the epicardial ST segment elevation and the degree of 
inhomogeneity of electrical activation were less pronounced in the PC dogs than in the non-
PC controls. 
It was demonstrated that the involvement of ROS is unlikely in this marked 
antiarrhythmic protection. This was proved by the use of MPG, a well known scavenger of 
ROS. MPG was applied in a dose (equivalent to a total intravenous dose of 90 mg kg−1) 
similar to that used in previous studies 83,  96,  97. It was given directly into a side branch of the 
coronary artery that was later occluded. The results show that such a locally administered 
MPG failed to modify the antiarrhythmic effects of preconditioning. The incidences of VF 
and VT, and the distribution of ventricular ectopic beats were similar in the preconditioned 
dogs irrespective of whether or not the scavenger had been given (Figures 2 and 3). 
Moreover, MPG given to control dogs (C + MPG) reduced the phase Ia arrhythmias (Figures 
2 and 3), a phenomenon that deserves further investigation. Nevertheless, the total number of 
VPBs in this group was not significantly different from the saline administered controls. 
Furthermore, the reduction of the two measured parameters of ischemia severity by 
preconditioning was not significantly modified by MPG, at least, during the first 5 to 8 
minutes of ischemia. It can be concluded that in this species under in vivo conditions ROS, 
and in particular superoxide, are not necessary for inducing early protection against life-
threatening arrhythmias. The protection is present even when a highly diffusible and effective 
scavenger had been administered. In contrast, this protection was abolished by blocking the 
bradykinin B2 receptors 109 or by inhibition of nitric oxide synthase 107 or cyclo-oxygenase 69. 
In this study the superoxide production during the PC procedure was also determined 
both in the absence and in the presence of MPG. The results clearly show that after the first 
PC occlusion there was no detectable superoxide formation. This could mean two things: 
either a single 5 minute occlusion is not sufficient to produce superoxide, or the superoxide 
production induced by the short PC occlusion was effectively scavenged by superoxide 
dismutase. There is only one free radical that is certainly released during the early phase of 
ischaemia is nitric oxide (NO). This is not scavenged by MPG, although NO in the presence 
of superoxide quickly forms peroxynitrite which can be scavenged by MPG. NO triggers the 
protection, possibly by involving the opening of the mitocondrial KATP channels and this 
would generate further free radical 110. More recently, Juhász and colleagues 111 showed that 
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scavenging the peroxynitrite by uric acid did not modify the early effect of IPC. However, the 
exogenously administered peroxynitrite induced similar antiarrhythmic protection, like PC 111.  
In an in vitro experiment the scavenging activity of MPG was demonstrated in PMCs 
using a ferricytochrome-c reduction assay. It was proven that the MPG can decrease the ROS 
formation by a concentration dependent manner. The applied in vitro doses of MPG are 
comparable with an in vivo dose of MPG. 
The role of ROS has been thoroughly investigated in the cardioprotective effects of 
preconditioning. In this respect the most relevant studies are those of Richard et al. 100, Tanaka 
et al. 96 and Baines et al. 55. Both Tanaka 88,  96 and Baines 55 have found, that in rabbits the 
administration of MPG, in doses lower than those used in the present study, prior to and 
during a single PC (5 min) occlusion, completely abolished the infarct size reducing effect of 
PC. However, Baines and colleagues 55 found that MPG failed to modify the preconditioning 
effect of four 5 minute occlusions. They proposed that other mediators (adenosine, 
bradykinin), that are released when multiple occlusions are used, may act together with ROS, 
thus inhibition of ROS formation only attenuates but not completely abolishes the protection. 
More ROS were generated by reperfusion after many occlusions compared to just one. 
Similarly, Richard and colleagues 100, using three preconditioning occlusions in rats, failed to 
demonstrate any effect of intravenously given MPG (20 mg kg−1). Furthermore, these authors 
also assessed arrhythmias during and following a 20 minute occlusion period following PC 
with three 5 minute occlusions, and found that MPG did not modify this protection. However, 
they did not distinguish between those arrhythmias that developed during the ischemic period 
and those that resulted from reperfusion. The results in this thesis are in agreement with those 
of Richard et al 100; i.e. the administration of MPG failed to modify the protective 
antiarrhythmic effect of ischemic preconditioning induced by two 5 minute occlusions.  
There was also no evidence that ROS are involved in arrhythmia severity when a 
coronary artery is occluded without preconditioning. The total number of arrhythmias was 
just as severe after MPG administration. This also accords with previous experience in this 
species 115. However the phase Ia arrhythmias disappeared after the MPG infusion. This 
finding could be a task of a further research.  
These results, of course, do not exclude the possibility that ROS are not involved in the 
early cardioprotection when this is induced by other stimuli or multiple ischemic/reperfusion 
insults. There is increasing evidence that the intensity of the preconditioning stimulus 
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determines the signalling pathways that leads to cardioprotection 116, 117. It should not be 
concluded from our studies that ROS generated during the preconditioning process (ischemia 
and reperfusion) do not contribute to the delayed effects of PC. However, it should be noted 
that most studies implicating free radicals as triggers for delayed protection against stunning 
and infarct size 76- 83 have used multiple coronary artery occlusions.  
There is one other effect of the coronary artery occlusion that was also not modified by 
MPG. When a coronary artery is occluded (e.g. the LAD, as in the present study), there is an 
immediate increase in blood flow in an adjacent main branch (e.g. the LCX). One explanation 
for this phenomenon might be that the compensatory increase in flow follows the increased 
oxygen demands from the area of the left ventricular wall. It can be due to the loss of 
contractility in the ischemic area. Increased oxygen requirements lead to a corresponding, 
matching increase in blood flow. This observation,  119- 121 still lacks a convincing explanation.  
5.2. The role of NO in the delayed antiarrhythmic effect of 
preconditioning induced by physical exercise 
The results of this part of the study confirm the previous observations of Babai and 
colleagues44 that vigorous treadmill exercise, which is sufficient to increase the heart rate over 
200 beats min-1 can protect the heart against life-threatening arrhythmias. The first evidence 
that protection against the ischemia and reperfusion arrhythmias can be achieved by 
increasing the heart rate was provided by 45 Végh et al. in 1991 44. This finding was confirmed 
by several later studies (Kaszala et al., 1996) 118. It is still not known precisely how cardiac 
pacing and physical exercise preconditions the heart against the severe consequences of 
myocardial ischemia. It seems likely that during cardiac pacing and exercise there is an 
increase in myocardial oxygen demand that results from the increased heart rate and this, 
together with an elevation of filling pressure within the left ventricle, is sufficient to elicit 
changes that leads to cardioprotection. 
The aim of the present research was to obtain further evidence that nitric oxide is 
involved in the delayed phase of preconditioning induced by heavy physical exercise. In this 
case two NOS inhibitors (L-NAME and the AEST) were used. A non-selective NOS inhibitor 
(L-NAME) was used before the exercise to examine the trigger activity of NO·in the process. 
A relatively selective iNOS inhibitor AEST was administrated before a prolonged 25 min 
occlusion period (24 h after the exercise trigger) to examine NO· as a mediator in the 
antiarrhythmic mechanisms. The single period of exercise induced beneficial effect against 
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arrhythmias (such as: VPBs and VT reduction, the rise of survival numbers, the reduced ST 
segment elevation) were abolished by both NOS inhibitors. 
The results from the application of two different NOS inhibitors suggest that NO plays 
both a trigger and a mediator role in this protection. Since the marked antiarrhythmic effects 
of exercise, as well as the reduced ischemic and haemodynamic changes that were apparent 
after exercise, were significantly attenuated by these inhibitors. Further it was supposed that 
NO is most likely derived from the inducible form of NOS enzyme, since the iNOS inhibitor 
AEST was as effective in reducing the protection as that was L-NAME. The observation 
revealed that the administration of L-NAME, given prior to the exercise stimulus, abolishes 
the delayed antiarrhythmic protection. It can be suggested that NO is generated as a result of 
exercise that acts as a trigger for the subsequent activation of iNOS (NO stimulated NO 
release). The early generation of NO is necessary for the delayed protection that results from 
exercise. One practical difficulty with the L-NAME study is that it proved impossible to reach 
a similar increase in heart rate (190–220 beats min -1) during exercise as that in those dogs 
which were not treated with L-NAME. This was because the administration of L-NAME 
resulted in a significant bradycardia.  
It can be suggested that it is the generation of NO from the constitutive enzyme during 
the single exercise period that induces further NO formation from iNOS 24 h later. There is 
evidence of such NO stimulated NO production; triggering the development of delayed 
preconditioning when myocardial stunning is used as the endpoint 95. The subsequent 
pathways include the activation of PKC 122 and tyrosine kinase 123,  124 resulting from the NO-
stimulated generation of cGMP 125 when the arrhythmias were used as the endpoint, although 
this is still a matter of debate 126. More recently it was shown in rats 127, that NO produced from 
cNOS (but not from iNOS) during preconditioning by brief periods of coronary artery 
occlusion, also triggers delayed preconditioning-induced endothelial protection 
Besides NO there are a number of other possible mediators of delayed cardioprotection 
that are released during exercise. These include catecholamines, which are able to induce late 
protection (for example against ischemia and reperfusion arrhythmias 128,  129,) through an 
adrenoceptor mediated PKC activation 130,  131 which then induces iNOS gene expression 132. 
Exercise also releases opioid peptides that act on δ-opioid receptors. This induces late 
preconditioning by a mechanism which involves the formation of prostacyclin and PGE2 133. 
However the results of the present study suggest that NO is a particularly important trigger 
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and mediator for exercise-induced protection against those life-threatening arrhythmias that 
result from acute coronary artery occlusion. 
5.3. Clinical relevance of preconditioning 
The highly effective methods of myocardial protection during coronary artery surgery 
were developed and used in chemical cardioplegia, hypothermia, and cross-clamp ventricular 
fibrillation. However the increasing number of surgical operation in elder and high risk 
patients implies that the protection and its methods always have to be improved 110. The 
pharmacology preconditioning might induce just one or two cellular pathways which can 
develop PC effect (e.g. adenosine or A1 receptor selective agonist 134- 135; stable analogue of 
prostacyclin 136- 137; bradykinin 138). Some of these have relevance in preconditioning during 
coronary angioplasty 139 or postoperative recovery of clinical applications 140 if it is used in 
combination with other PC stimulus. The ischemic preconditioning is utilized generally 
before some type of cardiac surgery (e.g. coronary artery bypass grafting, coronary stenosis 
enlarging) to prevent the heart from the following oxygen deficiency. This causes the most 
powerful protection during the surgical procedure. The rapid cardiac pacing is another 
mechanism that induces a myocardial preconditioning in clinical aspects. However the 
duration of this protection is not as long as induced by ischemic PC, the combination with 
IPC is applicable in the clinical practice 141. 
The exercise induced cardioprotection is the most complex mechanism of the 
protection. In this case the tachycardia, decreasing of blood perfusion, increase of energy and 
oxygen supply and remote effects may play a role in this process. Moreover the physical 
activity induces the metabolic pathways, which also has a beneficial effect. Exercise training 
in patients with elevated cardiovascular risk or established disease can increase the 
bioavailability of NO and other possible PC mediators, to help the development of secondary 
prevention 142. The exercise induced cardio-protection has a more prominent relevance in 
primary or secondary prevention. This complex mechanism is the simplest cardioprotection 
that could be produced day by day.  
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6. Summary and New Scientific Results 
The aim of this thesis was to investigate the non-receptor triggers and mediators in the 
early and late phase of preconditioning against arrhythmias.  
(1/a) The role of reactive oxygen species were examined in the early phase of protection 
induced by two five minute coronary occlusion, by the use of the ROS scavenger MPG. It was 
found that scavenging of ROS failed to modify the antiarrhythmic effect of PC, indicating that 
ROS does not play an essential role in the IPC induced early protection against arrhythmias. It 
can be proposed that this two five minute PC triggers the release of other mediators and 
stimulates simultaneous protecting pathways which predominate over ROS in the induction of 
the protection. 
(1/b) The ROS formation at different times was investigated during the experiment. It 
was found that after the second PC stimuli, there is a burst of detectable ROS. In the presence 
of MPG this burst of ROS disappeared.  
(1/c) The MPG treatment blocks the appearance of phase Ia arrhythmias during the 25 
minute of test occlusion but not the phase Ib. These were observed from the MPG treated 
control group (without PC stimuli). 
The other part of the research was to obtain further evidence for the involvement of nitric 
oxide in the delayed phase of the preconditioning-induced protection against arrhythmias. For 
this purpose two inhibitors of NOS were used. The PC stimulus was induced by physical 
exercise, 24 h before a 25 min occlusion and reperfusion insult. A single 21 min period of 
exercise 24 h prior to ischemia resulted in a marked protection against ventricular 
arrhythmias.  
(2/a) It was found that the beneficial, antiarrhythmic effect of treadmill exercise is 
abolished by the use of the eNOS inhibitor L-NAME before the 21 minutes of exercise.  
(2/b) The applied iNOS inhibitor, AEST, can block the protecting effect of the exercise if 
it is applied immediately before the test occlusion.  
This investigation with the applied two NOS inhibitors clearly demonstrates the role of 
NO as a trigger and a mediator in the exercise induced cardiac preconditioning against 
ventricular ectopic beats. 
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9. Appendix  
9.1. Összefoglaló 
Az elmúlt néhány évtizedben számos vizsgálat folyt a myocardium 
védőmechanizmusainak kialakítására, megelőzve a szív károsodását az ischemás/reperfúziós 
hatásoktól. Murray és kollégái elsőnek írták le a szív adaptációs képességét a hosszan tartó 
ischemiás állapothoz. A toleranciát rövid, ismétlődő ischemiás/reperfúziós periódusokkal 
alakították ki. Ezt a jelenséget ischemiás prekondícionálásnak nevezték. Az a tény, hogy a 
szív megvédhető a végzetes károsodásoktól a saját adaptációs képességének segítségével, a 
prekondícionálás kiváltásának folyamatát és mechanizmusát mind kísérletes mind klinikai 
területen a figyelem középpontjába emelte. A rövid, ischemiás periódusokkal kiváltott 
védőhatás mára általánosan használt klinikai módszer arra, hogy megvédjék a szívet a 
coronaria by-pass műtétek során. Mára számos bizonyíték szolgál arra, hogy a szívben a 
védőhatás nem csak a rövid érelzárások által lehet kiváltani, hanem a szívfrekvencia 
megnövelésével (cardiac pacing) ill. fizikai terheléssel is. Számos epidemiológiai vizsgálat 
szolgáltat adatokat arra vonatkozóan, hogy a rendszeres mozgás csökkenti a 
szívbetegségekben szenvedő páciensekben a betegség súlyosbodását és a halálozást. Továbbá 
a fizikális terhelés csökkenti a szívbetegségek kialakulásának kockázati tényezőit 
(hipertenzió, hiperlipidémia, diabetes, obezitás). Azonban a fizikális terhelés kiváltotta 
védőhatás pontos mechanizmusa még tisztázásra vár.  
Jelen doktori disszertáció fő témája a korai és késői antiarrhythmiás védőhatások 
mechanizmusainak vizsgálata volt, különös tekintettel a szabad gyökök és a nitrogén monoxid 
szerepére a védőhatás antiarrhythmiás folyamataiban. 
A disszertáció első fele a szabadgyökök szerepét vizsgálja a rövid érelzárásokkal 
kiváltott korai antiarrhythmiás folyamatokban, nyitott mellkasú kutya modellben. Szabadgyök 
fogóként N-2-marcaptopropionyl-glicint (MPG) alkalmaztunk. Az alkalmazott gyökfogó nem 
szüntette meg a rövid érelzárások kiváltotta antiarrhythmás védőhatást. In vitro vizsgálat 
igazolta, hogy a vérben lévő polimorfonukleáris sejtekben a szabadgyökök kiválthatók 
ferrocitokróm-c redukciós módszerrel. A kiváltott szabadgyökök gátolhatók MPG-vel. A 
kísérlet különböző időpontjaiban a sinus coronariusból vett vérminták analízise igazolta az 
alkalmazott MPG dózis hatásosságát, mely képes volt megkötni a felszabaduló szabadgyök 
 - 53 - 
mennyiségét. A vizsgálatok igazolták, hogy a kontroll csoportban alkalmazott MPG a teljes 
érelzárás alatt kialakuló arrhythmiák számát ugyan nem csökkentette, de az arrhythmiák Ia 
fázisát legátolta. 
A disszertáció másik fele a nitrogén monoxid szerepével foglalkozik a késői 
védőhatások antiarrythmiás folyamataiban. A védőhatást egyszeri (21 perces) futópadon 
történő fizikális terheléssel alakítottuk ki. A nitrogén monoxid szerepén két nitrogén monoxid 
szintáz gátlóval vizsgáltuk. A folyamatosan expresszálódó cNOS működését L-NAME 
alkalmazásával gátoltuk, közvetlenül a fizikális terhelés előtt. A kísérlet bebizonyította a NO 
trigger szerepét a fizikális terhelés kiváltotta antiarrhythmiás folyamatban. Másrészről 
vizsgáltuk a nitrogén monoxid mediátor szerepét a késői védőhatás kialakításában. E célból az 
indukálható NOS szelektív gátlóját az AEST-t alkalmaztuk. A vizsgálat igazolta, hogy a NO 
nem csak trigger de mediátor is a fizikális terhelés kiváltotta antiatthythmiás folyamatokban. 
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